MediLink Therapeutics (Suzhou) Co.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, MediLink Therapeutics (Suzhou) Co. sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
MediLink Therapeutics (Suzhou) Co.: 7 sponsored US clinical trials, 6 recruiting.
MediLink Therapeutics (Suzhou) Co. sponsors 7 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 3 trials.
Upper-quartile sponsor footprint
MediLink Therapeutics (Suzhou) Co. sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
NCT07407933
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
NCT06459973
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
NCT06384352
A Study of YL201 in Patients With Advanced Solid Tumors
NCT05434234
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
Therapeutic Areas
What is open in the MediLink Therapeutics (Suzhou) Co. pipeline
6 recruiting of 7 indexed (86% open).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (3 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
MediLink Therapeutics (Suzhou) Co.: open-pipeline peers nationwide
Peers matched on 7 registered trials and 86% open enrollment, not the therapeutic-area sidebar.
MediLink Therapeutics (Suzhou) Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 86% open enrollment (± trial volume)
- Johnson & Johnson Enterprise Innovation · 86% recruiting · 7 trials
- Centessa Pharmaceuticals (UK) Limited · 83% recruiting · 6 trials
- Meyer Children's Hospital IRCCS · 83% recruiting · 6 trials
- SystImmune · 83% recruiting · 6 trials
Related
What to do with this MediLink Therapeutics (Suzhou) Co. page
7 registered trials is a research-attention snapshot, not an endorsement of MediLink Therapeutics (Suzhou) Co. or any single study.
- 6 of MediLink Therapeutics (Suzhou) Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition MediLink Therapeutics (Suzhou) Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. MediLink Therapeutics (Suzhou) Co. pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.